Seulki Lee, PhD, President and Chief Executive Officer
Dr. Lee is the Founder, President and CEO of D&D Pharmatech and its subsidiary companies, Neuraly and Theraly Fibrosis.
He is Executive Chairman of Precision Molecular, Valted Seq and P4 Microbiome. Dr. Lee has been at the forefront of
Theranostic research, engineering biologics and materials for diagnosis, therapy and imaging. He is currently on
leave from Johns Hopkins School of Medicine where he is an associate professor of radiology
At Johns Hopkins, Dr. Lee has investigated the role of engineered biotherapeutics in fibrosis, cancer and neurodegenerative
diseases at the molecular level and in preclinical models. Dr. Lee has published more than 130 articles in peer-reviewed
journals and holds more than twenty patents for drug/protein delivery and diagnostics. Dr. Lee has received multiple awards,
including the NRC Associateship from the National Academy of Sciences, the NIH Pathway to Independence
Award, Career Development Award and Investigator-Initiated Research Award from the Department of Defense.
He earned his PhD at GIST in Korea and completed his post-doctoral studies at the Stanford University School of Medicine
and National Institutes of Health.
Viktor Roschke, PhD, Chief Scientific Officer, D&D Pharmatech, Neuraly and Theraly Fibrosis
Dr. Roschke is the Co-Founder and Chief Scientific Officer of D&D Pharmatech, Neuraly and Theraly Fibrosis
He has more than twenty years of experience in drug development for a broad range of indications including oncology,
inflammation, metabolic and neurological diseases. Most recently, Dr. Roschke was Vice-President and interim
CEO of Zyngenia where he led the discovery, optimization, manufacturing and early clinical development of multi-specific
antibody-based therapeutics. Prior to this, he was Vice-President of CoGenesys, a company spun out of Human Genome
Sciences that was later acquired by Teva Pharmaceuticals. At Human Genome Sciences he was head of clinical
immunology and antibody development.Dr. Roschke earned his PhD from Novosibirsk State University.
Sungmook Lim, PhD, Co-CEO
Dr. Lim co-founded D&D Pharmatech with his advisor, Dr. KangChoon Lee, and Dr. Seulki Lee in 2014 and has served
as a CEO since its inception.He received his PhD and is a former research professor at the School of Pharmacy,
Sungkyunkwan University. His research on developing bioengineered GLP-1r agonist and
TRAIL protein with KangChoon and Seulki was the first university technology licensed to
D&D Pharmatech and became NLY01 and TLY012.
Sunghoon Hong, KICPA, Chief Financial Officer
Mr. Hong is responsible for finance, investor relations and corporate communications. He has more than twenty years
of experience in executive roles at financial institutions. Prior to joining D&D Pharmatech in 2019, he was the Chief Financial
Officer at Dongkoo BioPharm. He previously worked at EastBridge Partners, an independent private
equity firm headquartered in Seoul, for more than seven years as partner. Prior to EastBridge, he worked at RK Capital,
STIC Investment and PwC Korea.
Martin Pomper, MD, PhD, Founder and Chief Executive Officer, Precision Molecular
Dr. Pomper is founder and CEO of Precision Molecular, Inc. and is a leader in the fields of nuclear medicine and molecular imaging.
He has conducted basic and clinical research in imaging for more than thirty years and has successfully translated
multiple products into the clinic.
Dr. Pomper is the Henry N. Wagner, Jr. Professor of Radiology and Director of the Division of Nuclear Medicine and Molecular Imaging
at the Johns Hopkins School of Medicine. He is the Director of the Center for Translational Molecular Imaging, the Johns Hopkins
PET Center and an Associate Dean for Entrepreneurship and Technology Development. He is a Fellow of the National Academy of
Medicine. Dr. Pomper has published more than 420 peer-reviewed articles.
He is board-certified in diagnostic radiology and nuclear medicine. His interests are in the development of new radiopharmaceuticals,
optical and magnetic resonance probes and techniques for molecular imaging and therapy of cancer, central nervous system
disease and other disorders. He received undergraduate, graduate and medical degrees from the University of Illinois at
Urbana-Champaign and underwent postgraduate medical training at Johns Hopkins including an internship on the Osler Medical
Service, diagnostic radiology residency, nuclear medicine residency and a fellowship in neuroradiology. He has been on the
Johns Hopkins faculty since 1995.
Ted Dawson MD, PhD, Founder and Chief Scientific Officer, Valted Seq
Dr. Dawson is a co-founder of Neuraly and co-founder and CSO of Valted Seq, Inc. He has dedicated his career to deciphering
the mechanisms that control neurodegeneration and neuronal cell death. His studies have provided major insights into understanding
the pathogenesis of Parkinson’s disease and relatedneurologic disorders. These pioneering studies have led to clinical trials of
disease modifying agents in Parkinson’s disease and other neurodegenerative diseases.
Dr. Dawson is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and the director of the Institute for Cell
Engineering at the Johns Hopkins University School of Medicine. He is an elected fellow of the American Association for the Advancement
of Science, the American Academy of Neurology and the American Heart Association. He has published more than 570 highly cited articles.
He is a member of the editorial board of several journals.
He is board-certified in neurology with a specialization in movement disorders. He has held leadership positions in several professional
organizations and currently serves on the Scientific Advisory Board of CurePSP. He served as the Chair of the Scientific Advisory
Board of the Bachmann-Strauss Dystonia and Parkinson’s Disease Foundation, served on the Advisory Council of Aligning Science Across
Parkinson's and the Executive Scientific Advisory Board of the Michael J. Fox Foundation. Professor Dawson has received over 60 honors
and awards including the Derek-Denny Brown Award and the Santiago Grisoliá Chair and Medal. He received his medical degree and
Ph.D. in pharmacology from the University of Utah School of Medicine.
Valina Dawson, PhD, Founder and Chief Executive Officer, Valted Seq
Dr. Dawson is co-founder and CEO of Valted Seq, Inc. and is an international scientific leader in the field of neuronal cell death and
neurodegeneration. She has led major research programs focused on regenerative medicine and protecting the nervous system
from injury. Dr. Dawson is a pioneer in the field that connects fundamental basic science to clinical insight in neurologic diseases,
which is leading to new clinical trials in Parkinson’s disease and other neurologic diseases.
She is a Daniel Nathans Innovator and the Director of the Programs in Neuroregeneration and Stem Cells at the Institute for Cell
Engineering at the Johns Hopkins University School of Medicine. She is an elected fellow of the American Association for the
Advancement of Science, American Neurological Association and the American Heart Association and has published more than
420 highly cited articles. She has received many honors including the Debrecen Award for Molecular Medicine.She obtained her
undergraduate degree at the University of California at Davis, her PhD at the University of Utah and completed postdoctoral
training at the University of Pennsylvania and the National Institutes of Health before joining the faculty at Johns Hopkins.